Literature DB >> 16766180

EUSOMA accreditation of breast units.

R W Blamey1, L Cataliotti.   

Abstract

EUSOMA (European Society of Mastology) is the organisation representing Breast Cancer Specialists in all disciplines, covering all aspects of breast cancer from risk and prevention, through diagnosis and treatment of the primary tumour, follow-up, treatment of recurrent and advanced disease, pathology, reconstruction, psychology and audit. EUSOMA Guidelines have been published on several aspects of breast cancer and are on service provision as well as giving clinical guidance and providing the basis for audit.

Entities:  

Mesh:

Year:  2006        PMID: 16766180     DOI: 10.1016/j.ejca.2006.04.003

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  Breast Centers in Germany.

Authors:  Ute-Susann Albert; Uwe Wagner; Matthias Kalder
Journal:  Breast Care (Basel)       Date:  2009-08-14       Impact factor: 2.860

2.  Optimizing the quality of breast cancer care at certified german breast centers: a benchmarking analysis for 2003-2009 with a particular focus on the interdisciplinary specialty of radiation oncology.

Authors:  Sara Y Brucker; Markus Wallwiener; Rolf Kreienberg; Walter Jonat; Matthias W Beckmann; Michael Bamberg; Diethelm Wallwiener; Rainer Souchon
Journal:  Strahlenther Onkol       Date:  2011-01-21       Impact factor: 3.621

Review 3.  Quality Assurance in Breast Health Care and Requirement for Accreditation in Specialized Units.

Authors:  Sertaç Ata Güler; Bahadır M Güllüoğlu
Journal:  J Breast Health       Date:  2014-07-01

4.  Organizational and welfare mode of breast centers network: a survey of Sicilian radiologists.

Authors:  Maria Adele Marino; Orazio Pennisi; Annalisa Donia; Carmelo Sofia; Claudio Guerra; Carmelo Privitera; Placido Romeo
Journal:  Radiol Med       Date:  2017-04-20       Impact factor: 3.469

5.  Diabetes and prognosis in a breast cancer cohort.

Authors:  Michael G Schrauder; Peter A Fasching; Lothar Häberle; Michael P Lux; Claudia Rauh; Alexander Hein; Christian M Bayer; Katharina Heusinger; Arndt Hartmann; Johanna D Strehl; David L Wachter; Rüdiger Schulz-Wendtland; Boris Adamietz; Matthias W Beckmann; Christian R Loehberg
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-05       Impact factor: 4.553

6.  Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer.

Authors:  M Schrauder; S Frank; P L Strissel; M P Lux; M R Bani; C Rauh; C C Sieber; K Heusinger; A Hartmann; R Schulz-Wendtland; R Strick; M W Beckmann; Peter A Fasching
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-09       Impact factor: 4.553

7.  Standard requirements for GCP-compliant data management in multinational clinical trials.

Authors:  Christian Ohmann; Wolfgang Kuchinke; Steve Canham; Jens Lauritsen; Nader Salas; Carmen Schade-Brittinger; Michael Wittenberg; Gladys McPherson; John McCourt; Francois Gueyffier; Andrea Lorimer; Ferràn Torres
Journal:  Trials       Date:  2011-03-22       Impact factor: 2.279

8.  Benchmarking the quality of breast cancer care in a nationwide voluntary system: the first five-year results (2003-2007) from Germany as a proof of concept.

Authors:  Sara Y Brucker; Claudia Schumacher; Christoph Sohn; Mahdi Rezai; Michael Bamberg; Diethelm Wallwiener
Journal:  BMC Cancer       Date:  2008-12-02       Impact factor: 4.430

9.  Certification of breast centres in Germany: proof of concept for a prototypical example of quality assurance in multidisciplinary cancer care.

Authors:  Sara Y Brucker; Michael Bamberg; Walter Jonat; Matthias W Beckmann; Andreas Kämmerle; Rolf Kreienberg; Diethelm Wallwiener
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

10.  A dynamic clinical pathway for the treatment of patients with early breast cancer is a tool for better cancer care: implementation and prospective analysis between 2002-2010.

Authors:  Peter A van Dam; Gerda Verheyden; Alessa Sugihara; Xuan B Trinh; Herman Van Der Mussele; Hilde Wuyts; Luc Verkinderen; Jan Hauspy; Peter Vermeulen; Luc Dirix
Journal:  World J Surg Oncol       Date:  2013-03-16       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.